D-0608-2017 Class III Terminated

Recalled by Pfizer Inc — Peapack, NJ

FDA drug recall D-0608-2017 was initiated by Pfizer Inc on Mar 7, 2017 and is designated Class III. Reason for recall: Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius. The recall status is terminated (terminated May 31, 2019). Affected quantity: 11,862 units.

Recall details

Product Type
Drugs
Report Date
Mar 29, 2017
Initiation Date
Mar 7, 2017
Termination Date
May 31, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,862 units

Product description

Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017 Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).

Reason for recall

Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.

Distribution pattern

Nationwide within US

Code information

Lot #: 03216026A, Exp. 02/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0608-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0608-2017. Report a data issue: hello@regdatalab.com.